CANbridge Pharmaceuticals Inc. (1228) AI Stock Analysis

• Market Cap: HK$1.21B
• Dividend Yield: N/A
• Average Volume (3M): 5.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -40.24%
• EPS Growth: 66.43%
• Country: HK
• Employees: 67
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.15
• Shares Outstanding: 510,826,480
• 10 Day Avg. Volume: 2,153,700
• 30 Day Avg. Volume: 5,027,972
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.11
• Price to Sales (P/S): 0.62
• P/FCF Ratio: -0.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: HK$2.00 ▼(-8.68% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by high operational losses and negative equity. Technical analysis provides a mixed outlook with some buying pressure but potential bearish momentum. Valuation metrics further highlight the company's financial challenges, with a negative P/E ratio and no dividend yield.

Positive Factors

Strategic Partnerships

Strategic partnerships provide funding and enhance the company's capability to bring products to market efficiently, supporting long-term growth.

Focus on Rare Diseases

Specializing in rare diseases and cancers positions CANbridge in niche markets with less competition and high unmet needs, supporting sustainable demand.

Government Grants

Potential government grants can provide financial support and reduce development costs, enhancing long-term financial stability.

Negative Factors

High Operational Losses

High operational losses and negative equity indicate financial instability, challenging the company's ability to achieve profitability and sustain operations.

Negative Cash Flow

Consistently negative cash flows highlight difficulties in generating cash from operations, increasing reliance on external financing and financial risk.

Declining Revenue Trend

Declining revenue trend and net losses suggest challenges in achieving sustainable growth, impacting long-term viability and competitive positioning.

CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model

Company Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.

How the Company Makes Money

CANbridge Pharmaceuticals generates revenue through multiple channels, primarily by developing and commercializing its proprietary drug candidates, which are in various stages of clinical trials. The company may earn income from product sales once its drugs receive regulatory approval and are launched in the market. Additionally, CANbridge often engages in strategic partnerships and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments tied to developmental achievements, and royalties on future sales. These partnerships not only provide funding but also enhance the company's capability to bring its products to market more efficiently. Furthermore, CANbridge may benefit from government grants or incentives aimed at fostering innovation in the healthcare sector, particularly for treatments addressing rare diseases.

CANbridge Pharmaceuticals Inc. Financial Statement Overview

Summary

CANbridge Pharmaceuticals Inc. faces significant financial hurdles with high operational losses and negative equity. The company's ongoing cash flow struggles and reliance on financing highlight the challenges in achieving financial sustainability. Strategic changes are needed to improve profitability and financial health in the highly competitive biotechnology sector.

Income Statement

The company shows a declining revenue trend with significant net losses. Gross profit margins are positive but are overshadowed by high negative EBIT and net profit margins due to substantial expenditures. Revenue growth has been inconsistent, demonstrating challenges in achieving sustainable growth in a competitive industry.

Balance Sheet

The company's balance sheet reflects high leverage with negative equity, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a risk in volatile markets. Despite a relatively low asset base, the company struggles with substantial liabilities, indicating potential liquidity issues.

Cash Flow

Operating and free cash flows are consistently negative, indicating challenges in generating positive cash flow from operations. The company's reliance on external financing is evident, and the cash flow to net income ratios highlight inefficiencies in converting profits into cash, exacerbating financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.56M	85.10M	102.87M	78.97M	31.16M	12.03M
Gross Profit	40.29M	54.30M	64.16M	48.89M	18.78M	6.88M
EBITDA	-150.16M	-328.69M	-341.43M	-454.63M	-1.06B	-824.41M
Net Income	-136.11M	-442.62M	-378.84M	-483.48M	-1.08B	-846.04M
Balance Sheet
Total Assets	105.50M	116.81M	395.36M	702.04M	892.52M	586.36M
Cash, Cash Equivalents and Short-Term Investments	1.96M	10.50M	137.49M	451.16M	745.82M	360.80M
Total Debt	34.97M	135.78M	141.93M	155.28M	52.10M	46.90M
Total Liabilities	514.58M	591.30M	435.15M	393.49M	199.13M	2.33B
Stockholders Equity	-409.08M	-474.49M	-39.79M	308.56M	693.39M	-1.75B
Cash Flow
Free Cash Flow	-14.19M	-122.50M	-319.09M	-315.76M	-592.40M	-305.13M
Operating Cash Flow	-14.10M	-122.39M	-278.23M	-280.98M	-587.07M	-151.65M
Investing Cash Flow	-38.00K	13.93M	-26.86M	-34.79M	126.09M	-153.48M
Financing Cash Flow	0.00	-18.57M	-28.02M	-20.70M	854.31M	679.26M

CANbridge Pharmaceuticals Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Positive. The current price of 2.19 is above the 20-day moving average (MA) of 2.11, above the 50-day MA of 2.14, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 53.89 is Neutral, neither overbought nor oversold. The STOCH value of 51.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1228.

CANbridge Pharmaceuticals Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2197	52 Neutral	HK$2.80B	-2.69	―	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1228	47 Neutral	HK$1.21B	-6.79	―	―	-40.24%	66.43%
2257	46 Neutral	HK$858.24M	―	―	―	―	83.89%
2126	41 Neutral	HK$1.53B	-2.26	-51.56%	―	2.45%	2.58%
6628	41 Neutral	HK$1.17B	―	-34.18%	―	-57.84%	24.58%
9939	36 Underperform	HK$815.90M	-4.26	-54.87%	―	―	81.67%

CANbridge Pharmaceuticals Inc. Corporate Events

CANbridge Pharmaceuticals Secures Shareholder Approval for Key Resolutions at EGM

CANbridge Pharmaceuticals Inc. announced that all resolutions proposed at their Extraordinary General Meeting (EGM) held on December 4, 2025, were passed by shareholders. The resolutions included granting a new general mandate to the company’s directors to issue shares and extending this mandate to shares repurchased by the company. This approval reflects strong shareholder support and may enhance the company’s financial flexibility, potentially impacting its strategic initiatives and market positioning.

CANbridge Pharmaceuticals to Hold Virtual EGM for Share Issuance Mandate

CANbridge Pharmaceuticals Inc. announced an extraordinary general meeting (EGM) to be held virtually on December 4, 2025. The meeting will address resolutions including the revocation of the existing general mandate for issuing shares and the approval of a new mandate allowing directors to issue additional shares up to 20% of the total shares in issue. This strategic move is aimed at enhancing the company’s flexibility in capital management and potentially strengthening its market position.

CANbridge Pharmaceuticals Announces EGM and Register Closure

CANbridge Pharmaceuticals Inc. announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 4, 2025. This meeting is significant for shareholders as it determines their eligibility to attend and vote, impacting the company’s governance and strategic decisions. The closure period is from December 1 to December 4, 2025, and shareholders must ensure their shares are registered by November 28, 2025, to participate. This announcement underscores the company’s commitment to structured shareholder engagement and could influence its operational and strategic direction.

CANbridge Pharmaceuticals Proposes New General Mandate for Share Issuance

CANbridge Pharmaceuticals Inc. has announced a proposal to refresh its Existing General Mandate, allowing directors to issue new shares up to 20% of the company’s issued share capital. This move comes after the full utilization of the existing mandate, and aims to provide the company with greater flexibility in managing its capital structure, potentially impacting its market positioning and offering new opportunities for investment.

CANbridge Pharmaceuticals Completes HK$22.59 Million Share Subscription

CANbridge Pharmaceuticals Inc. has successfully completed the subscription of new shares under a general mandate, issuing nearly 10 million shares at a price of HK$2.26 each, generating gross proceeds of approximately HK$22.59 million. This strategic move, involving independent subscribers, is expected to bolster the company’s financial position and support its operational plans, enhancing its market presence and potentially benefiting stakeholders by expanding its capital base.

CANbridge Pharmaceuticals to Raise HK$22.59 Million Through New Share Subscriptions

CANbridge Pharmaceuticals Inc. has entered into three subscription agreements to issue nearly 10 million new shares at a discounted price of HK$2.26 each, raising gross proceeds of approximately HK$22.59 million. The net proceeds will be used for research and development of existing products and daily operations, potentially strengthening the company’s financial position and enhancing its ability to innovate in the biopharmaceutical industry.